60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
60 Degrees Pharmaceuticals, Inc. (SXTP)
Company Research
Source: GlobeNewswire
90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatmentStudy will run approximately 12 months and enroll up to 100 patientsInternal estimates of the unmet medical need are between 4,400 and 190,000 cases annually, with no existing FDA-approved treatment for babesiosis WASHINGTON, Nov. 21, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the central study site for the Company’s B-FREE Chronic Babesiosis Study, the Cohen Center for Recovery from Complex Chronic Diseases at Mount Sinai Icahn School of Medicine, is open for patient enrollment. The study is the first to evaluate a therapeutic for chronic babesiosis and will run for approximately 12 months. The B-FREE Chronic Babesiosis Study (NCT06656351) is a Phase 2 open-label study that will ev
Show less
Read more
Impact Snapshot
Event Time:
SXTP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SXTP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SXTP alerts
High impacting 60 Degrees Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SXTP
News
- 60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its price target lowered by analysts at Ascendiant Capital Markets from $3.00 to $2.80. They now have a "buy" rating on the stock.MarketBeat
- 60 Degrees Pharmaceuticals (NASDAQ:SXTP) was upgraded by analysts at Zacks Research to a "hold" rating.MarketBeat
- 60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- 60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results [Yahoo! Finance]Yahoo! Finance
- 60 Degrees Pharmaceuticals Announces Third Quarter 2025 ResultsGlobeNewswire
SXTP
Sec Filings
- 11/13/25 - Form 10-Q
- 11/7/25 - Form SCHEDULE
- 11/7/25 - Form SCHEDULE
- SXTP's page on the SEC website